Breaking News Instant updates and real-time market news.

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

17:27
01/16/18
01/16
17:27
01/16/18
17:27

Celgene in discussions to acquire Juno Therapeutics, WSJ reports

Celgene (CELG) is in talks to acquire Juno Therapeutics (JUNO), the Wall Street Journal reports. The discussions could lead to a deal in the coming weeks, the report says, citing people familiar with the matter. Terms of a potential transaction could not be learned, the Journal noted. Reference Link

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

CELG Celgene
$104.82

-1.18 (-1.11%)

01/08/18
ADAM
01/08/18
NO CHANGE
Target $140
ADAM
Buy
Celgene acquisition has 'interesting' upside potential, says Canaccord
After Celgene announced a deal to acquire Impact Biosciences for up to $7B, including an upfront payment of $1.1B, Canaccord analyst John Newman said the latter's JAK2 asset for myelofibrosis, fedratinib, showed an "interesting" 55% response rate in patients resistant or intolerant to Jakafi, which provides an immediately approvable FDA indication. This "carefully structured transaction" provides Celgene with substantial upside, assuming FDA approval, said Newman, who keeps a Buy rating and $140 price target on Celgene shares.
01/08/18
PIPR
01/08/18
NO CHANGE
Target $100
PIPR
Neutral
Celgene guidance 'a bit light' on sales, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond views Celgene's preliminary Q4 results as "solid' but says the company's initial 2018 outlook is "a bit light" on revenue. The better than expected earnings outlook looks to be driven by expense management and lower than modeled share count, Raymond tell investors in a research note. He keeps a Neutral rating on Celgene with a $100 price target.
01/09/18
JEFF
01/09/18
NO CHANGE
Target $125
JEFF
Buy
Celgene likely 'too cheap and oversold,' says Jefferies
Jefferies analyst Michael Yee says that at 12 times earnings estimates, shares of Celgene are "probably too cheap and oversold." After meeting with management, Yee believes the company will do more deals following yesterday's acquisition of Impact. Further, he sees a potential share rebound on more pipeline readouts in 2018-2019. The analyst keeps a Buy rating on Celgene with a $125 price target.
01/09/18
BMOC
01/09/18
NO CHANGE
Target $147
BMOC
Outperform
Celgene 2018 outlook deliberately conservative, says BMO Capital
BMO Capital analyst M. Ian Somaiya says Celgene's 2018 guidance is "deliberately conservative", reflecting the management's decision to reduce the risk to near-term estimates amid investor focus on the company pipeline. Somaiya notes that investor focus is shifting to business development and the potential for more deals in the near-term as well as the data from the company's 12 phase III trials this year. The analyst keeps his Outperform rating and $147 price target on Celgene.
JUNO Juno Therapeutics
$45.60

-3.15 (-6.46%)

11/03/17
RAJA
11/03/17
NO CHANGE
Target $61
RAJA
Outperform
Juno Therapeutics price target raised to $61 from $45 at Raymond James
Raymond James analyst Reni Benjamin raised Juno Therapeutics' price target to $61 from $45 and reiterated his Outperform rating following the Q3 report and update on all ongoing clinical programs. The analyst believes JCAR017 could potentially be a differentiated CAR T product and compete effectively with Yescarta and Kymriah. Further, with key readouts from multiple programs anticipated at upcoming medical conferences, the steady progress of the portfolio of products, including the BCMA CAR-T franchise as well as 5 products targeting solid tumors with data expected in 2018, and a strong cash position, Benjamin continues to recommend shares.
12/12/17
WELS
12/12/17
DOWNGRADE
Target $54
WELS
Market Perform
Juno Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Juno Therapeutics (JUNO) to Market Perform and cut his price target for the shares to $54 from $66. While data for JCAR017 continue to support a potential best-in-class profile in aggressive lymphoma, the current valuation already reflects dominant market positioning over Gilead's (GILD) Yescarta, Birchenough tells investors in a research note. The analyst also sees "some risk" to waning efficacy at six months for JCAR017.
12/12/17
12/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Juno Therapeutics (JUNO) downgraded to Market Perform from Outperform at Wells Fargo, with analyst Jim Birchenough saying that while data for JCAR017 continue to support a potential best-in-class profile in aggressive lymphoma, the current valuation already reflects dominant market positioning over Gilead's (GILD) Yescarta. 2. General Dynamics (GD) downgraded to Underweight from Neutral at JPMorgan, with analyst Seth Seifman saying Gulfstream questions are unlikely to be resolved in the near term. Demand for G500/600 is ok for now, but uncertainty about ultimate production levels and the pace of the learning curve mean the transition will remain a near term overhang, the analyst said. Seifman also downgraded Raytheon (RTN) to Neutral from Underweight. 3. Adobe (ADBE), Barracuda (CUDA), GoDaddy (GDDY), Fortinet (FTNT) and Check Point (CHKP) downgraded to Neutral from Overweight and CoStar Group (CSGP), Imperva (IMPV) and Monotype Imaging (TYPE) downgraded to Underweight from Overweight at JPMorgan by analyst Sterling Auty in conjunction with his 2018 annual outlook for Software Technology. The analyst does not expect the "exceptional performance" in Software during 2017 to repeat in 2018. 4. Spark Therapeutics (ONCE) downgraded to Neutral from Buy at UBS, with analyst Carter Gould seeing a "challenging setup" for the shares after the Phase 1/2 SPK-8011 data in hemophilia A fell short of expectations. The analyst removed SPK-8011, or $29 per share, and early-stage pipeline value, or $12 per share, from his model. He finds it difficult to be more constructive on Spark shares in the near-term. 5. Electronic Arts (EA) downgraded to Buy from Conviction Buy at Goldman Sachs by analyst Christopher Merwin to reflect fewer near-term catalysts around in-game monetization of non-sports titles. To see The Fly's full Street Research coverage, click here.
01/05/18
NEED
01/05/18
INITIATION
Target $65
NEED
Buy
Juno Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Juno Therapeutics (JUNO) with a Buy rating and a price target of $65. Messer says that while Novartis (NVS) and Gilead (GILD) have reached the CAR-T technology market ahead of Juno, the latter is "developing safer and potentially better products", positioning itself with "best-in-class technology". The analyst believes that the selloff in the stock price since the December ASH conference creates an attractive near-term entry point for investors.

TODAY'S FREE FLY STORIES

VRX

Valeant

$18.58

-0.3 (-1.59%)

, TEVA

Teva

$19.98

-0.92 (-4.40%)

05:55
02/21/18
02/21
05:55
02/21/18
05:55
Recommendations
Valeant, Teva analyst commentary  »

Deutsche sees rifamycin…

VRX

Valeant

$18.58

-0.3 (-1.59%)

TEVA

Teva

$19.98

-0.92 (-4.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    May

  • 18

    Jun

  • 27

    Aug

BT

BT Group

$16.24

0.05 (0.31%)

05:49
02/21/18
02/21
05:49
02/21/18
05:49
Upgrade
BT Group rating change  »

BT Group upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

VLVLY

Volvo AB

$19.42

-0.03 (-0.15%)

05:47
02/21/18
02/21
05:47
02/21/18
05:47
Initiation
Volvo AB initiated  »

Volvo AB initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$78.85

-2.2 (-2.71%)

05:44
02/21/18
02/21
05:44
02/21/18
05:44
Recommendations
Trinseo analyst commentary  »

Trinseo valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$29.12

2.84 (10.81%)

05:42
02/21/18
02/21
05:42
02/21/18
05:42
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

05:40
02/21/18
02/21
05:40
02/21/18
05:40
General news
FX Action: USD-CAD clocked a 12-day high »

FX Action: USD-CAD…

PTLA

Portola Pharmaceuticals

$48.22

0.53 (1.11%)

05:34
02/21/18
02/21
05:34
02/21/18
05:34
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola selloff overdone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 04

    May

MRK

Merck

$54.98

-1.31 (-2.33%)

05:34
02/21/18
02/21
05:34
02/21/18
05:34
Hot Stocks
Merck to acquire Viralytics for about $394M »

Merc and Viralytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Oct

BHVN

Biohaven Pharmaceutical

$29.58

-0.03 (-0.10%)

, CTLT

Catalent

$42.48

-0.89 (-2.05%)

05:30
02/21/18
02/21
05:30
02/21/18
05:30
Hot Stocks
Biohaven Pharmaceutical announces exclusive license with Catalent »

Biohaven Pharmaceutical…

BHVN

Biohaven Pharmaceutical

$29.58

-0.03 (-0.10%)

CTLT

Catalent

$42.48

-0.89 (-2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 04

    Mar

  • 03

    May

BHP

BHP Billiton

$46.55

-2.14 (-4.40%)

, RIO

Rio Tinto

$56.27

-1.55 (-2.68%)

05:30
02/21/18
02/21
05:30
02/21/18
05:30
Downgrade
BHP Billiton, Rio Tinto rating change  »

BHP Billiton downgraded…

BHP

BHP Billiton

$46.55

-2.14 (-4.40%)

RIO

Rio Tinto

$56.27

-1.55 (-2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

VJET

voxeljet

$4.00

-0.534 (-11.79%)

05:27
02/21/18
02/21
05:27
02/21/18
05:27
Recommendations
voxeljet analyst commentary  »

voxeljet making progress…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLDP

Ballard Power

$3.29

-0.08 (-2.37%)

05:27
02/21/18
02/21
05:27
02/21/18
05:27
Hot Stocks
Ballard Power receives follow-on purchase order from Nisshinbo Holdings »

Ballard Power Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 11

    Mar

  • 29

    Mar

  • 23

    May

NFLX

Netflix

$278.55

0.03 (0.01%)

05:24
02/21/18
02/21
05:24
02/21/18
05:24
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 20

    Mar

SMCI

Super Micro Computer

$18.85

-0.25 (-1.31%)

05:19
02/21/18
02/21
05:19
02/21/18
05:19
Hot Stocks
Super Micro Computer receives non-compliance letter from Nasdaq »

Super Micro Computer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXFT

Luxoft

$43.55

0.1 (0.23%)

, AMZN

Amazon.com

$1,468.35

19.66 (1.36%)

05:18
02/21/18
02/21
05:18
02/21/18
05:18
Recommendations
Luxoft, Amazon.com analyst commentary  »

Luxoft 20% share pullback…

LXFT

Luxoft

$43.55

0.1 (0.23%)

AMZN

Amazon.com

$1,468.35

19.66 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

PSA

Public Storage

$186.31

-2.44 (-1.29%)

05:17
02/21/18
02/21
05:17
02/21/18
05:17
Hot Stocks
Public Storage announces CEO, CFO succession plan »

Public Storage announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NBL

Noble Energy

$29.12

2.84 (10.81%)

05:15
02/21/18
02/21
05:15
02/21/18
05:15
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

ALLE

Allegion

$85.66

2.94 (3.55%)

05:12
02/21/18
02/21
05:12
02/21/18
05:12
Recommendations
Allegion analyst commentary  »

Allegion price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$42.10

0.54 (1.30%)

05:10
02/21/18
02/21
05:10
02/21/18
05:10
Downgrade
Match Group rating change  »

Match Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOS

Mosaic

$26.76

1.33 (5.23%)

05:07
02/21/18
02/21
05:07
02/21/18
05:07
Upgrade
Mosaic rating change  »

Mosaic upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

FOGO

Fogo De Chao

$15.55

3 (23.90%)

05:06
02/21/18
02/21
05:06
02/21/18
05:06
Downgrade
Fogo De Chao rating change  »

Fogo De Chao downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCT

Corporate Capital Trust

$14.63

-0.12 (-0.81%)

05:04
02/21/18
02/21
05:04
02/21/18
05:04
Initiation
Corporate Capital Trust initiated  »

Corporate Capital Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

INOV

Inovalon

05:01
02/21/18
02/21
05:01
02/21/18
05:01
Hot Stocks
Inovalon announces resignation of CFO, COO Christopher Greiner »

Inovalon announced last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

HSBC

HSBC

$52.02

-1.81 (-3.36%)

04:57
02/21/18
02/21
04:57
02/21/18
04:57
Downgrade
HSBC rating change  »

HSBC downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

BT

BT Group

$16.24

0.05 (0.31%)

04:56
02/21/18
02/21
04:56
02/21/18
04:56
Upgrade
BT Group rating change  »

BT Group upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.